Related references
Note: Only part of the references are listed.Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys
Xiaomin Su et al.
HUMAN GENE THERAPY (2009)
Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy
Chee Yeun Chung et al.
JOURNAL OF NEUROSCIENCE (2009)
Axonal Transport Defects in Neurodegenerative Diseases
Gerardo A. Morfini et al.
JOURNAL OF NEUROSCIENCE (2009)
EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2-MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSON'S DISEASE
Christopher D. Herzo et al.
NEUROSURGERY (2009)
From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease
Peter Jenner
PARKINSONISM & RELATED DISORDERS (2009)
Role of axonal transport in neurodegenerative diseases
Kurt J. De Vos et al.
ANNUAL REVIEW OF NEUROSCIENCE (2008)
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks et al.
LANCET NEUROLOGY (2008)
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum
Christopher D. Herzog et al.
MOLECULAR THERAPY (2008)
AAV2 - mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease
Mehdi Gasmi et al.
NEUROBIOLOGY OF DISEASE (2007)
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D. Herzog et al.
MOVEMENT DISORDERS (2007)
Issues regarding gene therapy products for Parkinson's disease: The development of CERE-120 (AAV-NTN) as one reference point
Raymond T. Bartus et al.
PARKINSONISM & RELATED DISORDERS (2007)
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease
Mehdi Gasmi et al.
MOLECULAR THERAPY (2007)
Point source concentration of GDNF may explain failure of phase II clinical trial
Michael F. Salvatore et al.
EXPERIMENTAL NEUROLOGY (2006)
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Crossroads in GDNF therapy for Parkinson's disease
TB Sherer et al.
MOVEMENT DISORDERS (2006)
Axonal transport defects: a common theme in neurodegenerative diseases
S Roy et al.
ACTA NEUROPATHOLOGICA (2005)
Localized striatal delivery of GDNF as a treatment for Parkinson disease
D Kirik et al.
NATURE NEUROSCIENCE (2004)
Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects
Y Ai et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2003)
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
JG Nutt et al.
NEUROLOGY (2003)
Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor
D Kirik et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2000)
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
JH Kordower et al.
SCIENCE (2000)
On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis
RT Bartus
EXPERIMENTAL NEUROLOGY (2000)
Share Paper
